Cyclobenzaprine (Flexeril) and Orphenadrine Have Equivalent Efficacy as Muscle Relaxants
Neither cyclobenzaprine nor orphenadrine is definitively "stronger" than the other—both are centrally-acting skeletal muscle relaxants with similar modest efficacy for acute musculoskeletal pain, and the choice between them should be based on side effect profile and patient-specific contraindications rather than potency.
Evidence for Equivalent Efficacy
The most recent and rigorous comparative data comes from a 2022 emergency department study that directly compared seven skeletal muscle relaxants, including both cyclobenzaprine and orphenadrine 1. This analysis of randomized controlled trials found:
- Cyclobenzaprine: Mean improvement in Roland-Morris Disability Questionnaire (RMDQ) of 10.1 (95% CI 8.3-12)
- Orphenadrine: Mean improvement in RMDQ of 9.5 (95% CI 7.4-11.5)
- Placebo: Mean improvement in RMDQ of 10.5 (95% CI 9.5-11.5)
The between-group differences were not statistically significant, and neither drug outperformed placebo when combined with NSAIDs 1. This finding is consistent across age groups, sex, and baseline pain severity.
Mechanism of Action Differences
While efficacy is similar, the drugs work through different mechanisms:
Cyclobenzaprine
- Acts as a centrally-acting 5-HT2 receptor antagonist 2
- Structurally related to amitriptyline with tricyclic properties 3
- Works primarily at brainstem level, reducing tonic somatic motor activity 3
- Has potent peripheral and central anticholinergic effects 2
Orphenadrine
- Structurally similar to diphenhydramine 2
- Precise mechanism unclear but includes anticholinergic properties 4
- Does not directly relax tense muscles 4
- May have mild analgesic properties independent of muscle relaxation 5
Side Effect Profile: The Key Differentiator
Cyclobenzaprine has a worse adverse effect profile 1:
Cyclobenzaprine Side Effects
- More adverse medication effects than placebo (p < 0.01) 1
- Anticholinergic effects: hallucinations, confusion, drowsiness, constipation, urinary retention, dry mouth 2
- Sedation is prominent
- Risk of serotonin syndrome when combined with MAO inhibitors 2
- Withdrawal symptoms (malaise, nausea, headache) after long-term use, though not life-threatening 2
Orphenadrine Side Effects
- Anticholinergic symptoms: confusion, anxiety, tremors, urinary retention, dry mouth, constipation 2
- Cardiovascular instability 2
- Should be used with caution in patients with tachycardia, cardiac decompensation, coronary insufficiency, and arrhythmias 2
Clinical Practice Recommendations
When to Choose Cyclobenzaprine
- Patient without significant cardiac disease
- When sedation might be beneficial (e.g., pain interfering with sleep)
- Avoid in elderly due to anticholinergic burden
- Avoid with MAO inhibitors or other serotonergic drugs
When to Choose Orphenadrine
- Patient with insomnia is NOT desired (less sedating than cyclobenzaprine in practice)
- Avoid in patients with:
Important Caveats
Both drugs have limited evidence for chronic pain 6. The 2007 American Pain Society/American College of Physicians guideline found skeletal muscle relaxants moderately superior to placebo only for short-term (2-4 days) acute low back pain 6. Duration of therapy in trials was 2 weeks or less 6.
Neither drug should be first-line therapy. A 2018 systematic review concluded that skeletal muscle relaxants should be used only for short-term relief of acute low back pain when NSAIDs or acetaminophen are not effective or tolerated 7. The 2020 American College of Physicians guideline found no significant difference between any skeletal muscle relaxant and placebo for GI or neurologic adverse events individually, but cyclobenzaprine combined with ibuprofen increased neurologic adverse events (OR 4.91) 8.
Perioperative Management
Both medications should be held on the day of operation according to the 2021 SPAQI consensus statement 2:
- Cyclobenzaprine: Hold on day of operation; taper over 2-3 weeks if discontinuing long-term use 2
- Orphenadrine: Hold on day of operation 2
Bottom Line
Neither drug is "stronger"—they are essentially equivalent in efficacy and both barely outperform placebo for acute musculoskeletal pain. The choice should be driven by contraindications and side effect tolerance rather than perceived potency. Given cyclobenzaprine's higher rate of adverse effects 1 and orphenadrine's significant cardiac contraindications 2, many clinicians may prefer other options entirely, such as NSAIDs or acetaminophen as first-line therapy, reserving muscle relaxants for short-term use only when first-line agents fail.